Cita APA (7a ed.)

Bartl, T., Onoprienko, A., Hofstetter, G., Müllauer, L., Poetsch, N., Fuereder, T., . . . Grimm, C. (2021). Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. MDPI AG.

Cita Chicago Style (17a ed.)

Bartl, Thomas, Arina Onoprienko, Gerda Hofstetter, Leonhard Müllauer, Nina Poetsch, Thorsten Fuereder, Paul Kofler, Stephan Polterauer, y Christoph Grimm. Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. MDPI AG, 2021.

Cita MLA (8a ed.)

Bartl, Thomas, et al. Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. MDPI AG, 2021.